



DECODE THE BLEEDING PHENOTYPE

One Platform. One Sample. Under One Hour.

Automated Thrombin Generation Analysis for Hemophilia Research

Integrated Workflow

TGA + Routine Coagulation + Factor VIII + Factor XIII on a single automated platform. No more juggling multiple instruments or batching delays.

Proven Precision


Fully automated design with two independent pipetting arms to help minimize variability, ensuring reproducible results.

Rapid Time-to-Data


Turn-around-time in **as few as 25 minutes**, depending on sample type, and fewer than 5 minutes hands-on with lot stable calibration eliminates traditional batching requirements. Run samples on-demand when answers are needed now.

Novel Therapeutics Ready

Protocols for Emicizumab, gene therapy, bypassing agents, and non-Factor replacements. Measure what chromogenic or clotting factor based assays cannot.



TGA Comparison Adjusted Labels



ceveron
s 1 0 0
technoclon

Stop Compromising Your Research

Discover why HTCs are ditching manual or semi-automated thrombin generation assays and switch to the Ceveron advantage.

For research use only. Not for use in diagnostic procedures.



Overcome Your Research Hurdles With the **Ceveron s100**

The Problem	The Solution
Single factor assays can over or underestimate the effects of non-factor therapies, providing an incomplete and potentially misleading picture of bleeding risk.	The Ceveron® s100 Generation Assay provides a global, dynamic assessment of whole coagulation, accurately reflecting the <i>in vivo</i> hemostatic state and the impact of novel therapies.
Manual assay preparation and lack of standardization lead to inconsistent results, compromising the integrity of your data.	The Ceveron® s100 is fully automated and combines with lot-stable reference curves, ensuring high precision and reproducibility for reliable data comparisons across time and sites.
Manual TGA measurements are hard to interpret.	Normalized results on the Ceveron® s100 help to compare TGA coagulation status to a normal population.
Running multiple specialized assays on different platforms and sample types is inefficient, requires significant hands-on time, and increases the risk of error.	The Ceveron® s100 combines basic clotting, chromogenic, and turbidimetric coagulation tests with fluorescent TGA and quenching ADAMTS13 and Factor XIII assays into a single automated platform, streamlining your workflow and saving valuable research time.
Factor levels don't explain bleeding phenotype variability. Identical levels of Factor VIII can generate vastly different thrombin profiles.	The Ceveron® s100 captures the full hemostatic picture—tissue factor pathway, amplification, and inhibition—explaining why some 2% Factor VIII bleed severely while others are nearly asymptomatic.

Transform your hemophilia research program. Schedule a meeting with one of our experts today.



It's not just support. It's solutions.

800.526.5224 | info@diapharma.com | diapharma.com



For research use only. Not for use in diagnostic procedures. Ceveron is a registered trademark of Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

ML-07-00064 Rev01